Apellis Pharmaceuticals Data From GALE Extension Trial Of SYFOVRE Demonstrates Delayed Geographic Atrophy Lesion Growth By ~1.5 Years In Patients With Nonsubfoveal GA

Author: Benzinga Newsdesk | November 12, 2025 07:15am

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The results demonstrate that both every-other-month and monthly SYFOVRE delayed GA lesion growth by approximately 1.5 years in patients with nonsubfoveal GA when compared to sham/projected sham.

The safety profile of SYFOVRE through five years remained consistent with previously reported data. Detailed results will be presented at a future medical meeting.

GALE (n=792) is a Phase 3, multicenter, open-label, extension study to evaluate the long-term efficacy and safety of SYFOVRE® (pegcetacoplan injection) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The objectives of the study are to evaluate the long-term incidence and severity of ocular and systemic treatment emergent adverse events as well as change in the total area of GA lesions as measured by fundus autofluorescence. More than 80 percent of participants who completed the OAKS and DERBY studies entered the GALE study.

 

Posted In: APLS